ALISO VIEJO, Calif., June 26, 2015 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCQB:CNSO) CNS Response is ranked as one of 25 leading patent holders in pervasive neurotechnology, according to a recently released report on over 800 organizations by researcher SharpBrains. CNS Response is ranked 21st, based on the strength of its intellectual property, in the report titled "Pervasive Neurotechnology: A Groundbreaking Analysis of 10,000+ Patent Filings Transforming Medicine, Health, Entertainment, and Business." Other firms ranked according to the IP Strength Index include the Nielsen Company (#1 overall), Medtronic (#3), Microsoft (#4), Neuronetics (#8), Accenture (#10), General Electric (#11), IBM (#14), and Stanford University (#23). The SharpBrains analysis values the neurotech patent portfolio at $2 billion USD in 2015.
A graph accompanying this release is available at http://media.globenewswire.com/cache/21222/file/35237.pdf
The report highlights "an explosion in relevant patent filings and grants," noting 500% growth in active patents and pending applications in the last 10 years. CNS Response is identified as a category leader in Key Active EEG Patents, for its "broad claim coverage of quantified assessments of neurophysiological info for correlating medication response profiles." Other EEG leaders include the Nielsen Company (#1), Phillips (#18), and Sedline/Masimo (#20).
"The ability to gather and analyze objective and predictive brain data, in order to better personalize pharma and non-pharma treatments, is quickly becoming paramount," said Alvaro Fernandez, SharpBrains CEO and editor-in-chief of the new report. "We were gladly surprised to see how innovative firms like CNS Response have started to harness the potential of EEG and cloud-based platforms to radically upgrade brain health."
The Company's original patents were filed by founder Stephen Suffin, MD, and its intellectual property counsel Medlen & Carroll (www.medlencarroll.com).
"We combine strong intellectual property with open science – through the PEER Registry – to deliver objective prescribing information to clinicians," said George Carpenter, CEO. "It's technology that can help people today, with the potential to accelerate discovery and transform the treatment of brain disorders in the future."
More information about the SharpBrains report can be obtained at http://sharpbrains.com/pervasive-neurotechnology.
About CNS Response Inc.
CNS Response (www.cnsresponse.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company's Psychiatric EEG Evaluation Registry, or PEER Online, is a clinical registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). PEER is now the largest database of neurophysiological findings correlated to medication response, with 38,000 outcomes for over 10,000 unique patients in the PEER registry. 12 clinical studies have documented its value in reducing trial and error treatment, which is currently the dominant approach in the treatment of brain disorders.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response representatives at PEERinfo@cnsresponse.com.
About SharpBrains
SharpBrains is an independent market research firm and think tank tracking applications of cognitive and affective neuroscience, with special emphasis on non-invasive neurotechnologies.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
